Fem Dophilus
Jarrow - 60 caps

• The Most Effective Probiotic for Women's Health
• GR-1 & RC-14 Clinically Documented Lactobacillus
• For Women's Internal Balance
• Oral Probiotic for Natural Vaginal Health
• Patented Lactobacilli: GR-1™ and RC-14®
• Prevention Magazine: Top 10 Breakthrough '07
  

fem-dophilus® contains two patented and clinically documented probiotic strains, Lactobacillus rhamnosus GR-1® and Lactobacillus reuteri RC-14®, discovered and developed by Dr. Gregor Reid and Dr. Andrew Bruce at Urex Biotech. Over 20 years of research supports the oral use of GR-1® and RC-14® to colonize and protect the vaginal tract.

Clinical trials have shown that GR-1® and RC-14®:

• Help to maintain or restore healthy vaginal flora that are important in maintaining vaginal health*
• Support the health of the urinary tract*

fem-dophilus® is manufactured under pharmaceutical GMP conditions with guaranteed potency and consistency. The probiotic strains in fem-dophilus® are in a proprietary polysaccharide matrix, which protects the bacteria from stomach acid and enhances probiotic bacteria survival to the lower intestine.

Supplement Facts Serving Size: 1 Capsule Servings Per Container: 60
		Amount Per Serving		% Daily Value
	Total Probiotic Bacteria	5	billion cfu	**
	Lactobacillus rhamnosus GR-1
	Lactobacillus reuteri RC-14
**Daily Value not established.

Studies:
Lawson Health Research Institute, Canadian Research and Development Center for Probiotics, 268 Grosvenor Street, London, ON, Canada N6A 4V2. gregor@uwo.ca

Urogenital infections afflict an estimated one billion people each year. The size of this problem and the increased prevalence of multi-drug resistant pathogens make it imperative that alternative remedies be found. A randomized, placebo-controlled trial of 64 healthy women given daily oral capsules of Lactobacillus rhamnosus GR-1 and Lactobacillus fermentum RC-14 for 60 days showed no adverse effects. Microscopy analysis showed restoration from asymptomatic bacterial vaginosis microflora to a normal lactobacilli colonized microflora in 37% women during lactobacilli treatment compared to 13% on placebo (P=0.02). Lactobacilli were detected in more women in the lactobacilli-treated group than in the placebo group at 28 day (P=0.08) and 60 day (P=0.05) test points. Culture findings confirmed a significant increase in vaginal lactobacilli at day 28 and 60, a significant depletion in yeast at day 28 and a significant reduction in coliforms at day 28, 60 and 90 for lactobacilli-treated subjects versus controls. The combination of probiotic L. rhamnosus GR-1 and L. fermentum RC-14 is not only safe for daily use in healthy women, but it can reduce colonization of the vagina by potential pathogenic bacteria and yeast.

Other Ingredients :
Dextrose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate (vegetable source). Capsule consists of gelatin and titanium dioxide.

Contains:
Dairy (casein, in trace amounts). No wheat, no gluten, no soybeans, no egg, no fish/shellfish, no peanuts/tree nuts.

Product Notes:
Keep Refrigerated

Suggested Usage:
For maintenance, take 1 capsule orally per day and increase to 2 capsules per day as needed, or take as directed by your qualified health care consultant.

These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure or prevent any disease.